A dataset of adult heart and liver mass after placental Insulin-like growth factor 1 overexpression and insufficiency in mice

This study presents a dataset demonstrating that placental-targeted overexpression of Insulin-like growth factor 1 (IGF1) in mice leads to sexually dimorphic increases in adult heart and liver mass, whereas IGF1 insufficiency results in no significant changes, thereby highlighting the critical role of placental IGF1 in long-term organ development.

The Gist

Imagine your body is a high-tech construction project. The placenta is the on-site foreman and supply depot, responsible for sending out the essential blueprints and building materials (hormones) that tell the baby's organs how to grow. One of the most important "foremen" it sends out is a signal called IGF1 (Insulin-like growth factor 1).

This study is like a scientific experiment where the researchers decided to mess with the foreman's instructions to see what happens to the construction of two specific rooms in the house: the heart and the liver.

Here is the breakdown of what they did and what they found, using some everyday analogies:

The Experiment: Tweaking the Foreman

The researchers used a genetic tool called CRISPR (think of it as a very precise pair of "genetic scissors" or a "copy-paste" tool) to change the instructions sent by the placenta in mice. They did two things:

1. The "Overdrive" Team: They told the placenta to send out too many IGF1 signals (Overexpression).
2. The "Shortage" Team: They told the placenta to send out too few IGF1 signals (Insufficiency).

They waited until the mice grew up into adults to check the size of their hearts and livers.

The Big Discovery: It Depends on the "Gender" of the Mouse

The most interesting part of this story is that the results weren't the same for everyone. It's like a recipe that tastes different depending on who is eating it. The effects were sex-specific:

• For the Female Mice (The "Overdrive" Group):
  When the female mice received too many IGF1 signals from the placenta, their hearts grew significantly larger than normal. Imagine a factory that suddenly gets a massive order for parts; the heart room in the female mice expanded to handle the extra work.

  • Result: Bigger hearts in adult females.

• For the Male Mice (The "Overdrive" Group):
  The male mice with the same "too many signals" didn't get bigger hearts. However, their livers showed a slight, "trending" increase in size. It's as if the extra instructions went to a different department in the factory for the males.

  • Result: Slightly bigger livers in adult males.

• For the "Shortage" Group (Both Sexes):
  When the researchers reduced the IGF1 signals, nothing much happened to the size of the hearts or livers in the adult mice. The construction crew seemed to have enough backup plans to keep the rooms a normal size, even with fewer instructions.

Why Does This Matter?

Think of the placenta as the foundation of a building. If the foundation is laid with the wrong mix of concrete (hormones), the whole building might end up with structural issues years later.

• Heart Health: The study suggests that if a mother's placenta produces too much IGF1, it might permanently change how a female's heart develops, potentially making it larger. This is important because heart size is linked to heart health.
• Liver Health: Similarly, the liver in males might be sensitive to these early signals, which could relate to metabolic diseases (like fatty liver disease) later in life.
• The "DOHaD" Concept: This fits into a big idea called "Developmental Origins of Health and Disease." It basically means that what happens to you in the womb (like the amount of hormones you get) can set the stage for your health as an adult.

The Caveats (The Fine Print)

The authors are careful to point out that this was a "forced" experiment. They used genetic tools to create an artificial environment that doesn't happen naturally. Also, they only looked at the mice when they were fully grown, so they don't know if the organs changed size earlier in life and then shrank back down.

The Bottom Line

This paper tells us that the placenta isn't just a passive delivery service; it's an active boss that can shape the future of an animal's organs. Crucially, it treats boys and girls differently. By understanding these early "instructions," scientists hope to one day prevent or treat heart and liver diseases that start before we are even born.

Technical Summary

1. Problem Statement

The study addresses the critical role of the placenta in fetal development and its long-term impact on offspring health, specifically through the Developmental Origins of Health and Disease (DOHaD) hypothesis. While it is established that the placenta produces essential hormones like Insulin-like growth factor 1 (IGF1) which regulate fetal growth, the specific mechanisms by which placental Igf1 expression influences the long-term development of specific organs (heart and liver) remain understudied. Furthermore, there is a need to understand how these developmental disruptions manifest in a sexually dimorphic manner, given that placental function and hormonal responses often differ between male and female offspring. The authors aim to determine whether altering placental Igf1 levels (via overexpression or insufficiency) leads to permanent changes in adult heart and liver mass.

2. Methodology

The researchers employed a targeted genetic manipulation approach in a murine model to investigate these effects:

• Animal Model: Female CD-1 mice were bred with CD-1 males. Embryonic day 0 (E0) was defined by the presence of a copulation plug.
• Intervention (CRISPR Manipulation): On Embryonic Day 12 (E12), dams underwent surgical procedures to expose uterine horns. Individual placentas within the litter were injected with specific plasmids and electroporated to induce genetic changes:
  • Igf1-Overexpression (Igf1-OE): Using an IGF-I CRISPR Activation Plasmid.
  • Igf1-Insufficiency (Igf1-KO): Using an IGF-I CRISPR/Cas9 KO Plasmid (resulting in a hypomorphic state where expression is knocked out in some, but not all, placental cells).
  • Controls: Two control groups received either a Control CRISPR Activation Plasmid (ConAct) or a Control CRISPR/Cas9 plasmid (ConCas9).
• Postnatal Protocol: Offspring were weaned at postnatal day 21 into sex-specific group housing.
• Data Collection: At 12–14 weeks of age (adulthood), mice were euthanized. Body mass was recorded, followed by transcardial perfusion. Hearts and livers were dissected and weighed immediately.
• Statistical Analysis: Data were analyzed using GraphPad Prism. Outliers were removed via the ROUT test. Comparisons between experimental groups and their respective controls were performed using an unpaired Welch's t-test, stratified by sex. Significance was set at p < 0.05, with trends defined as p < 0.1.

3. Key Contributions

• Sex-Specific Developmental Insights: The study provides empirical data demonstrating that placental Igf1 manipulation results in sexually dimorphic outcomes for organ mass, highlighting that male and female fetuses respond differently to the same hormonal perturbations.
• Long-Term Organ Impact: It establishes a link between mid-gestation placental genetic changes and adult organ phenotypes, specifically showing that early-life placental Igf1 overexpression can lead to increased heart mass in adult females.
• Methodological Application: The paper validates the use of in utero CRISPR electroporation at E12 as a viable method for modeling placental insufficiency and overexpression to study long-term metabolic and cardiovascular outcomes.

4. Results

The study found significant differences in organ mass based on sex and the type of Igf1 manipulation:

• Heart Mass:
  • Females (Igf1-OE): Showed a significant increase in absolute heart mass (+13.06%) and proportional heart mass (+10.31%) compared to controls.
  • Males (Igf1-OE): No significant changes were observed.
  • Insufficiency (Igf1-KO): No significant changes in heart mass were detected in either sex.
• Liver Mass:
  • Females (Igf1-OE): No statistically significant increase was found, though averages showed a trend similar to heart mass increases.
  • Males (Igf1-OE): Showed a trending increase in proportional liver mass (+4.53%, p < 0.1).
  • Insufficiency (Igf1-KO): No significant impact on liver mass was observed in either sex.
• Body Mass: No significant changes in total adult body mass were observed across any experimental group compared to controls.

5. Significance

• Mechanistic Understanding of DOHaD: The data supports the hypothesis that early genetic disruptions in the placenta can program lifelong changes in organ structure, potentially predisposing individuals to chronic diseases like congenital heart defects or metabolic liver disorders (e.g., nonalcoholic fatty liver disease).
• Sexual Dimorphism in Disease Risk: The findings underscore the importance of considering sex as a biological variable in developmental biology. The fact that Igf1 overexpression affects female hearts and trends toward affecting male livers suggests distinct developmental pathways regulated by the interaction between IGF1 and sex hormones.
• Therapeutic Implications: By identifying specific windows (E12) and mechanisms (placental Igf1 levels) that alter adult organ health, this research lays the groundwork for future interventions targeting placental insufficiencies to prevent long-term metabolic and cardiovascular diseases.
• Limitations & Future Directions: The authors note that the CRISPR manipulation creates an artificial environment and may not perfectly mimic physiological ranges. Additionally, the effects were measured only in adulthood, meaning transient changes during development were not captured. Future research is needed to explore the functional consequences of these mass changes and the specific molecular pathways involved.